Effect of adrenocorticotropic hormone infusion on circulating sclerostin levels.

Zaheer S, Meyer K, Easly R, Bayomy O, Leung J, Koefoed AW, Heydarpour M, Freeman R, Adler GK

Endocrine connections14 Dec 2021Cited by 3 (Europe PMC)

PMID34788228PMCIDPMC8679878DOI10.1530/ec-21-0263PepBankPUB-34788228

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialMechanism
In healthy adults, cosyntropin increased serum cortisol significantly, whereas cortisol fell during placebo infusion.
In plain wordsIn healthy adults, cosyntropin increased cortisol while cortisol fell during placebo infusion.
Peptide
Cosyntropin
Outcome
IncreaseSerum cortisol
Study
n = 17
Comparator
Placebo infusion
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
As anticipated, cosyntropin significantly increased serum cortisol levels, whereas cortisol levels fell during placebo infusion, consistent with the diurnal variation in cortisol.
2 context sentences(design, population, supporting numbers)
Summary · context
This study was performed using blood samples obtained from a previously published, double-blind, placebo-controlled, randomized, cross-over study among healthy men and women who received infusions of placebo or cosyntropin after being supine and fasted overnight (ClinicalTrials.gov NCT02339506).
Summary · context
A total of 17 participants were analyzed.
Report a problemFND-3478822801
02HumanRandomized controlled trialMechanism
In healthy adults, cosyntropin did not significantly affect serum sclerostin versus placebo over 6-24 h (P = 0.10).
In plain wordsIn healthy adults, cosyntropin did not significantly change serum sclerostin compared with placebo.
Peptide
Cosyntropin
Outcome
No significant changeSerum sclerostin
Study
n = 17
Comparator
Placebo infusion
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
There was no significant effect of cosyntropin as compared to placebo infusions on serum sclerostin over 6-24 h (P = 0.10).
2 context sentences(design, population, supporting numbers)
Summary · context
This study was performed using blood samples obtained from a previously published, double-blind, placebo-controlled, randomized, cross-over study among healthy men and women who received infusions of placebo or cosyntropin after being supine and fasted overnight (ClinicalTrials.gov NCT02339506).
Summary · context
A total of 17 participants were analyzed.
Report a problemFND-3478822802

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT02339506

Stress and the Nervous System

Brigham and Women's Hospitaln = 23Apr 2015 to Nov 2020

Autonomic Nervous System · Baroreflex · Stress, Physiological

Trial page ClinicalTrials.govUpdated 3 Dec 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.